(AGENPARL) – lun 07 ottobre 2024 Lund, Sweden, 7 October 2024. Hansa Biopharma AB, (“Hansa” or the “Company”)
(Nasdaq Stockholm: HNSA), today announced positive results from a 12-month
follow up analysis from the NICE-01 trial of HNSA-5487, the Company’s next
generation immunoglobulin G (IgG)-cleaving molecule, assessing IgG recovery,
immunogenicity and redosing potential.
In the NICE-01 trial, HNSA-5487 demonstrated rapid and highly robust reduction
of IgG levels by more than 95 percent within a few hours post treatment. In a 12
-month follow up analysis IgG levels returned to normal range six months after
initial dosing. This confirms that HNSA-5487 mirrors the extremely high efficacy
of imlifidase, the Company’s first-generation IgG-cleaving enzyme, in reducing
total IgG levels. No serious adverse events were observed and as previously
communicated HNSA-5487 is safe and well tolerated.
Importantly, HNSA-5487 demonstrated lower pre-treatment anti-drug antibody (ADA)
levels and significantly reduced ADA responses when compared to imlifidase,
confirming an attractive immunogenicity profile with a clear redosing potential.
HNSA-5487 also demonstrated highly robust reduction in IgG levels with similar
efficacy in nearly 100 percent of serum samples collected in the trial and
analyzed at six- and 12-months after the initial dose.
Søren Tulstrup, President and CEO, Hansa Biopharma said, “There is mounting
clinical evidence that faster and more robust IgG reduction is directly linked
to more successful therapeutic outcomes in autoimmune and other diseases. We are
very encouraged by these results that demonstrate HNSA-5487 can robustly and
very rapidly reduce IgG levels, has redosing potential, and a favorable safety
and tolerability profile. We believe HNSA-5487 has a highly differentiated
profile compared to published data from studies with other IgG-targeted
therapies. These results underscore the transformational potential of HNSA-5487
to address significant unmet need across a spectrum of IgG driven diseases and
conditions, including autoimmune where there is a clear need for better
management of initial and repeat immune system attacks.”
The Company will focus clinical development of HNSA-5487 in chronic autoimmune
diseases where IgG plays a role in disease pathology and acute phases. Initial
clinical development of HNSA-5487 will focus in myelin oligodendrocyte
glycoprotein antibody disease (MOGAD), neuromyelitis optica (NMO) and myasthenia
gravis (MG). MOGAD affects 2 – 3.4 in every 100,000 people worldwide and
approximately 30 percent of all cases are in children.[1] NMO affects
approximately seven in every 100,000 people in the US and approximately 22,000
people in the US are living with the condition.[2] Globally, approximately 150
to 200 out of every million people have MG.[3]
These conditions have a common underlying cause: misguided IgG antibodies.
Despite the serious nature of these diseases, unmet medical need remains high
with few advanced therapies available, and no treatments approved for the acute
phases. HNSA-5487 can effectively and quickly reduce IgG levels, potentially
addressing a diverse range of debilitating symptoms caused by these conditions.
NICE-01 is a double blind, randomized, placebo-controlled trial evaluating
safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single
ascending doses of HNSA-5487 administered as a single intravenous (IV) infusion.
The trial included a total of 36 healthy male and female adult participants.
There were no serious adverse events and as previously communicated HNSA-5487
was safe and well tolerated.
Hansa Biopharma will host a telephone conference on 7 October at 14:00
CET / 8:00 AM EST.
Slides used in the presentation will be available online following the call.
To participate in the telephone conference, please use the dial-in details
provided below:
Participant Dial In (Toll Free): 1-877-270-2148
Participant International Dial In: 1-412-902-6510
*Please ask to be joined into the Hansa Biopharma call
Join the webcast here:
https://event.choruscall.com/mediaframe/webcast.html?webcastid=6iGh9S4f (https://
eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fevent.choruscall.com%2F
mediaframe%2Fwebcast.html%3Fwebcastid%3D6iGh9S4f&data=05%7C02%7Cstephanie.kenney%
40hansabiopharma.com%7C4eb9bfb020934c9da47508dcdd9a25c3%7C2baeedcdecb6405a84aaec9
AiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C4000%7C%7C%7C&sdata=WLiRg2wOkY
yb%2B%2BsbtiP333PevINSa0om0BY5MfjTFH8%3D&reserved=0)
— ENDS —
Contacts for more information:
Evan Ballantyne, Chief Financial Officer
Stephanie Kenney, VP Global Corporate Affairs
Notes to editors
About HNSA-5487 and the Novel IgG Cleaving Enzyme for Repeat Dosing (NiceR)
Program
HNSA-5487 is Hansa Biopharma’s next-generation IgG-cleaving enzyme with the
potential to prolong the IgG-low window. In 2023, Hansa conducted the first-in
-human trial of HNSA-5487 (NICE-01) reporting positive high-level results on
safety and tolerability and observing complete depletion of IgG antibodies at
increasing doses.
NiceR is Hansa Biopharma’s next generation IgG-cleaving enzyme program. It is in
preclinical development and is designed to enable expansion into a large
spectrum of potential indications, including relapsing autoimmune diseases and
gene therapy, as well as oncology indications. The lead molecule in the NiceR
program is HNSA-5487.
About imlifidase
Imlifidase is an antibody-cleaving enzyme originating from Streptococcus
pyogenes that specifically targets and cleaves immunoglobulin G (IgG) antibodies
and inhibits IgG-mediated immune response.[4] It has a rapid onset of action,
cleaving IgG-antibodies and inhibiting their activity within hours after
administration.
Imlifidase has conditional marketing approval in Europe and is marketed under
the trade name IDEFIRIX[®] for the desensitization treatment of highly
sensitized adult kidney transplant patients with a positive crossmatch against
an available deceased donor.
The use of IDEFIRIX should be reserved for patients who are unlikely to be
transplanted under the available kidney allocation system, including
prioritization programs for highly sensitized patients.[4] IDEFIRIX was reviewed
as part of the European Medicines Agency’s (EMA) Priority Medicines (PRIME)
program, which supports medicines that may offer a major therapeutic advantage
over existing treatments or benefit patients without treatment options.[4]
The efficacy and safety of imlifidase as a pre-transplant treatment to reduce
donor-specific IgG was studied in four phase 2 open-label, single-arm, six
-month clinical trials.[5,6,7]
Hansa is collecting further clinical evidence and will submit
additional efficacy and safety data based on one observational follow-up study
and one post-approval efficacy study.
Full product information can be accessed via the initial Summary of Product
Characteristics found here (https://www.ema.europa.eu/en/documents/product
-information/idefirix-epar-product-information_en.pdf).
About Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD)
MOGAD is an inflammatory disorder of the central nervous system characterized by
attacks of immune-mediated demyelination predominantly targeting the optic
nerves, brain, and spinal cord.[8] It is associated with the presence of
antibodies directed against myelin oligodendrocyte glycoprotein (MOG).
MOG is found in the myelin that insulates the nerves of the central nervous
system, which consists of the brain, spinal cord and optic nerves. The antibody
attack on MOG?disrupts the transmission of nerve signals in the body and causes
a variety of symptoms including changes in vision, weakness and numbness of the
limbs, and paralysis.[9]
MOGAD affects 2 – 3.4 in every 100,000 people worldwide and approximately 30
percent of all cases are in children.[1]
About Neuromylelitis Optica (NMO)
NMO is a rare autoimmune disease of the central nervous system (CNS) that mainly
affects the optic nerves and spinal cord. It is sometimes referred to as NMO
spectrum disorder or NMOSD.
In NMO, the body’s immune system mistakenly attacks healthy cells and proteins
in the body, most often those in the spinal cord and eyes. Symptoms include eye
pain and vision loss, weakness or paralysis of arms and legs, and severe
vomiting and nausea. There is no cure for NMO, and relapses and attacks are
often treated with corticosteroid drugs and plasma exchange.[10]
NMO affects approximately seven in every 100,000 people in the US. About 22,000
people in the US are living with the condition.[2]
About Myasthenia Gravis (MG)
MG is a rare, chronic autoimmune neuromuscular disorder that is characterized by
fluctuating weakness of the voluntary muscle groups. Approximately half of all
people with MG will experience weakness in the eye (ocular) muscles first, which
can include double vision, blurred vision and drooping eyelids. Eight out of 10
people with MG will develop more widespread weakness including in the neck,
face, arms or legs.[11,12]
Current immunomodulatory treatments do not achieve sufficient improvement or
resolution of symptoms and more targeted therapies are needed.[13]
Globally, approximately 150 to 200 out of every million people have MG. In the
US it is estimated that 37 out of every 100,000 people have MG.[3]
About Hansa Biopharma
Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a
mission to develop and commercialize innovative, lifesaving and life-altering
treatments for patients with rare immunological conditions. Hansa Biopharma has
developed a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme
therapy, which has been shown to enable kidney transplantation in highly
sensitized patients. Hansa Biopharma has a rich and expanding research and
development program based on the Company’s proprietary IgG-cleaving enzyme
technology platform, to address serious unmet medical needs in transplantation,
autoimmune diseases, gene therapy and cancer. Hansa Biopharma is based in Lund,
Sweden, and has operations in Europe and the U.S. The company is listed on
Nasdaq Stockholm under the ticker HNSA. Find out more at http://www.hansabiopharma.com
and follow us on LinkedIn (https://www.linkedin.com/company/hansa-medical-ab/).
©2024 Hansa Biopharma. Hansa Biopharma, the beacon logo, and IDEFIRIX are
trademarks of Hansa Biopharma AB, Lund, Sweden. All rights reserved.
References
1. Hor, Jyh Yung, and Kazuo Fujihara. “Epidemiology of myelin oligodendrocyte
glycoprotein antibody-associated disease: a review of prevalence and incidence
2. Briggs FB, Shaia J. Prevalence of neuromyelitis optica spectrum disorder in
the United States. Multiple Sclerosis Journal. 2024;30(3):316-324.
3. Dresser L, Wlodarski R, Rezania K, et al. Myasthenia gravis: epidemiology,
pathophysiology and clinical manifestations. J Clin Med 2021; 10: 2235.
4. European Medicines Agency. Idefirix[®] summary of product characteristics.
Available at: https://www.ema.europa.eu/en/documents/product
-information/idefirix-epar-product-information_en.pdf.
5. Jordan SC, et al. IgG Endopeptidase in Highly Sensitized Patients Undergoing
Transplantation. N Engl J Med  2017;377:442-453. DOI: 10.1056/NEJMoa16125
6. Winstedt L, et al. Complete Removal of Extracellular IgG Antibodies in a
Randomized Dose-Escalation Phase I Study with the Bacterial Enzyme IdeS–A Novel
7. Jordan SC, et al. Imlifidase Desensitization in Crossmatch-positive, Highly
Sensitized Kidney Transplant Recipients: Results of an International Phase 2
Trial (Highdes). Transplantation. 2021 Aug 1;105(8):1808-1817. doi:
8. Flanagan E, et al. Myelin oligodendrocyte glycoprotein antibody-associated
disease (MOGAD): Clinical features and diagnosis. Available at
https://www.uptodate.com/contents/myelin-oligodendrocyte-glycoprotein-antibody
-associated-disease-mogad-clinical-features-and-diagnosis#references. Accessed
on 17 September, 2024.
9. MOGAD Disorder and Multiple Sclerosis: Understanding Myelin Oligodendrocyte
Glycoprotein Antibody Disease (MOGAD). National MS Society. March 2023.
https://www.nationalmssociety.org/understanding-ms/what-is-ms/related
-conditions/mogad. Accesses 17 September 2024.
10. Neuromyletis optica (NMO). Available at https://www.ninds.nih.gov/health
-information/disorders/neuromyelitis-optica. Accessed on 17 September 2024.
11. Dresser L, Wlodarski R, Rezania K, et al. Myasthenia gravis: epidemiology,
pathophysiology and clinical manifestations. J Clin Med 2021; 10: 2235.
12. Punga A, Maddison P, Heckmann J, et al. Epidemiology, diagnostics, and
biomarkers of autoimmune neuromuscular junction disorders. Lancet Neurol 2022;
21: 176–188.
13. Schneider-Gold, Christiane, and Nils Erik Gilhus. “Advances and challenges
in the treatment of myasthenia gravis.” Therapeutic advances in neurological
If you would rather not receive future communications from Hansa Biopharma AB, please go to https://optout.ne.cision.com/en/HYW4DKhDJKj4ACqaKYTTCFEEc3AsLJnmeVdxK8znigDjiJAPuxjUME3aAMWFXCcvwbJNHKMmqCk9Re7JufqAAEvYKczfu2WgspmiQj1etbSZ8.
Hansa Biopharma AB, Scheelevägen 22, Lund, 22362 Sweden
————————————————————
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
If you would rather not receive future communications from Hansa Biopharma AB, please go to https://optout.ne.cision.com/en/HYW4DKhDJKj4ACqaKYTTCFEEc3AsLJnmeVdxK8znigDjiJAPuxjUME3aAMWFXCcvwbJNHKMmqCk9Re7JufqAAEvYKczfu2WgspmiQj1etbSZ8.
Hansa Biopharma AB, Scheelevägen 22, Lund, 22362 Sweden
Report this content